{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:46:40Z","timestamp":1787838400231,"version":"build-2784847793"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Janssen Global Medical Affairs"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Assess relationship between earlier clinical improvement and radiographic progression (RP) over 2\u00a0years in guselkumab-treated patients with active psoriatic arthritis (PsA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>Post\u00a0hoc analyses combined data from DISCOVER-2 biologic-na\u00efve adults with active PsA randomized to either guselkumab 100\u00a0mg every 4\u00a0weeks (Q4W) or guselkumab at W0, W4, then Q8W. Correlations (Spearman\u2019s coefficient) between baseline disease parameters and total PsA-modified van der Heijde-Sharp (vdH-S) score were examined. Repeated-measures mixed models, adjusted for known RP risk factors, assessed the relationship between Disease Activity Index in PsA (DAPSA) improvement, DAPSA improvement exceeding the median or the minimal clinically important difference (MCID), or DAPSA low disease activity (LDA) at W8 and RP rate, assessed by change from baseline in vdH-S score through W100.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Baseline age, PsA duration, CRP level, and swollen joint count, but not psoriasis duration\/severity, weakly correlated with baseline vdH-S score. Elevated baseline CRP (parameter estimate [\u03b2]\u2009=\u20090.17\u20130.18, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.03) and vdH-S score (\u03b2\u2009=\u20090.02, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) significantly associated with greater RP through W100. Greater improvement in DAPSA (\u03b2\u2009=\u2009-0.03, <jats:italic>p<\/jats:italic>\u2009=\u20090.0096), achievement of DAPSA improvement\u2009&gt;\u2009median (least squares mean [LSM] difference: -0.66, <jats:italic>p<\/jats:italic>\u2009=\u20090.0405) or\u2009&gt;\u2009MCID (-0.67, <jats:italic>p<\/jats:italic>\u2009=\u20090.0610), or DAPSA LDA (-1.44, <jats:italic>p<\/jats:italic>\u2009=\u20090.0151) by W8 with guselkumab significantly associated with less RP through W100. The effect of W8 DAPSA LDA on future RP was strengthened over time among achievers vs. non-achievers (LSM difference enhanced from -1.05 [<jats:italic>p<\/jats:italic>\u2009=\u20090.0267] at W52 to -1.84 [<jats:italic>p<\/jats:italic>\u2009=\u20090.0154] at W100).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In guselkumab-treated patients with active PsA, earlier improvement in joint symptoms significantly associated with lower RP rates through 2\u00a0years, indicating blockade of the IL-23 pathway may modify long-term disease course and prevent further joint damage.\n<jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td align=\"left\" colspan=\"2\">Key Points\u2022 <jats:italic>Greater improvement in DAPSA at Week 8 of guselkumab treatment was significantly associated with less progression of structural joint damage at 2\u00a0years in patients with active psoriatic arthritis (PsA).<\/jats:italic>\u2022 <jats:italic>Early control of peripheral joint disease activity with blockade of the IL-23 pathway may modify long-term PsA trajectory and prevent further joint damage.<\/jats:italic><\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-023-06745-y","type":"journal-article","created":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T11:02:16Z","timestamp":1696330936000},"page":"241-249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Earlier clinical response predicts low rates of radiographic progression in biologic-na\u00efve patients with active psoriatic arthritis receiving guselkumab treatment"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2927-8618","authenticated-orcid":false,"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-0775","authenticated-orcid":false,"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6462-4280","authenticated-orcid":false,"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7957-838X","authenticated-orcid":false,"given":"Soumya D.","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7427-8246","authenticated-orcid":false,"given":"Emmanouil","family":"Rampakakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2059-7866","authenticated-orcid":false,"given":"Alexa","family":"Kollmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xie L.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6005-3938","authenticated-orcid":false,"given":"May","family":"Shawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5213-257X","authenticated-orcid":false,"given":"Frederic","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4007-1589","authenticated-orcid":false,"given":"Mitsumasa","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4521-2029","authenticated-orcid":false,"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,3]]},"reference":[{"key":"6745_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","volume":"7","author":"O FitzGerald","year":"2021","unstructured":"FitzGerald O, Ogdie A, Chandran V et al (2021) Psoriatic arthritis. Nat Rev Dis Primers 7:59. https:\/\/doi.org\/10.1038\/s41572-021-00293-y","journal-title":"Nat Rev Dis Primers"},{"key":"6745_CR2","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","volume":"42","author":"D Kane","year":"2003","unstructured":"Kane D, Stafford L, Bresnihan B et al (2003) A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology 42:1460\u20131468. https:\/\/doi.org\/10.1093\/rheumatology\/keg384","journal-title":"Rheumatology"},{"key":"6745_CR3","first-page":"304","volume":"28","author":"L Congi","year":"2010","unstructured":"Congi L, Roussou E (2010) Clinical application of the CASPAR criteria for psoriatic arthritis compared to other existing criteria. Clin Exp Rheumatol 28:304\u2013310","journal-title":"Clin Exp Rheumatol"},{"key":"6745_CR4","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1136\/annrheumdis-2017-211433","volume":"76","author":"A Kerschbaumer","year":"2017","unstructured":"Kerschbaumer A, Baker D, Smolen JS et al (2017) The effects of structural damage on functional disability in psoriatic arthritis. Ann Rheum Dis 76:2038\u20132045. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211433","journal-title":"Ann Rheum Dis"},{"key":"6745_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N et al (2022) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 18:465\u2013479. https:\/\/doi.org\/10.1038\/s41584-022-00798-0","journal-title":"Nat Rev Rheumatol"},{"key":"6745_CR6","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A et al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79:700\u2013712. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217159","journal-title":"Ann Rheum Dis"},{"key":"6745_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/BOR.0000000000000147","volume":"27","author":"PJ Mease","year":"2015","unstructured":"Mease PJ (2015) Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol 27:127\u2013133. https:\/\/doi.org\/10.1097\/BOR.0000000000000147","journal-title":"Curr Opin Rheumatol"},{"key":"6745_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/1744666X.2020.1857733","volume":"17","author":"WH Boehncke","year":"2021","unstructured":"Boehncke WH, Brembilla NC, Nissen MJ (2021) Guselkumab: the first selective IL-23 inhibitor for active psoriatic arthritis in adults. Expert Rev Clin Immunol 17:5\u201313. https:\/\/doi.org\/10.1080\/1744666X.2020.1857733","journal-title":"Expert Rev Clin Immunol"},{"key":"6745_CR9","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH et al (2020) Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 395:1115\u20131125. https:\/\/doi.org\/10.1016\/S0140-6736(20)30265-8","journal-title":"Lancet"},{"key":"6745_CR10","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB et al (2020) Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 395:1126\u20131136. https:\/\/doi.org\/10.1016\/S0140-6736(20)30263-4","journal-title":"Lancet"},{"key":"6745_CR11","unstructured":"TREMFYA\u00ae (guselkumab). Highlights of prescribing information.\u00a0https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/TREMFYA-pi.pdf. Accessed\u00a015 Feb 2023"},{"key":"6745_CR12","doi-asserted-by":"publisher","first-page":"e001457","DOI":"10.1136\/rmdopen-2020-001457","volume":"7","author":"CT Ritchlin","year":"2021","unstructured":"Ritchlin CT, Helliwell PS, Boehncke WH et al (2021) Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-na\u00efve or TNF\u03b1 inhibitor-experienced. RMD Open 7:e001457. https:\/\/doi.org\/10.1136\/rmdopen-2020-001457","journal-title":"RMD Open"},{"key":"6745_CR13","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/art.41553","volume":"73","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Rahman P, Gottlieb AB et al (2021) Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis. Arthritis Rheumatol 73:604\u2013616. https:\/\/doi.org\/10.1002\/art.41553","journal-title":"Arthritis Rheumatol"},{"key":"6745_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Rahman P, Gottlieb AB et al (2022) Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol 74:475\u2013485. https:\/\/doi.org\/10.1002\/art.42010","journal-title":"Arthritis Rheumatol"},{"key":"6745_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/rheumatology\/keac375","volume":"62","author":"LC Coates","year":"2023","unstructured":"Coates LC, Ritchlin CT, Gossec L et al (2023) Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. Rheumatology (Oxford) 62:606\u2013616. https:\/\/doi.org\/10.1093\/rheumatology\/keac375","journal-title":"Rheumatology (Oxford)"},{"key":"6745_CR16","doi-asserted-by":"publisher","first-page":"e002789","DOI":"10.1136\/rmdopen-2022-002789","volume":"9","author":"AB Gottlieb","year":"2023","unstructured":"Gottlieb AB, McInnes IB, Rahman P et al (2023) Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naive patients with active psoriatic arthritis. RMD Open 9:e002789. https:\/\/doi.org\/10.1136\/rmdopen-2022-002789","journal-title":"RMD Open"},{"key":"6745_CR17","doi-asserted-by":"publisher","first-page":"e002038","DOI":"10.1136\/rmdopen-2021-002038","volume":"7","author":"C Borst","year":"2021","unstructured":"Borst C, Alasti F, Smolen JS et al (2021) Role of clinical and biochemical inflammation in structural progression of patients with psoriatic arthritis. RMD Open 7:e002038. https:\/\/doi.org\/10.1136\/rmdopen-2021-002038","journal-title":"RMD Open"},{"key":"6745_CR18","doi-asserted-by":"publisher","first-page":"R113","DOI":"10.1186\/ar3049","volume":"12","author":"DD Gladman","year":"2010","unstructured":"Gladman DD, Mease PJ, Choy EH et al (2010) Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther 12:R113. https:\/\/doi.org\/10.1186\/ar3049","journal-title":"Arthritis Res Ther"},{"key":"6745_CR19","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3899\/jrheum.180971","volume":"46","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Gladman DD, FitzGerald O et al (2019) Radiographic progression according to baseline C-reactive protein levels and other risk factors in psoriatic arthritis treated with tofacitinib or adalimumab. J Rheumatol 46:1089\u20131096. https:\/\/doi.org\/10.3899\/jrheum.180971","journal-title":"J Rheumatol"},{"key":"6745_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41927-019-0052-0","volume":"3","author":"AC Bay-Jensen","year":"2019","unstructured":"Bay-Jensen AC, Platt A, Jenkins MA et al (2019) Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis. BMC Rheumatol 3:3. https:\/\/doi.org\/10.1186\/s41927-019-0052-0","journal-title":"BMC Rheumatol"},{"key":"6745_CR21","doi-asserted-by":"publisher","first-page":"R86","DOI":"10.1186\/ar4266","volume":"15","author":"AS Siebuhr","year":"2013","unstructured":"Siebuhr AS, Bay-Jensen AC, Leeming DJ et al (2013) Serological identification of fast progressors of structural damage with rheumatoid arthritis. Arthritis Res Ther 15:R86. https:\/\/doi.org\/10.1186\/ar4266","journal-title":"Arthritis Res Ther"},{"key":"6745_CR22","doi-asserted-by":"publisher","first-page":"e001679","DOI":"10.1136\/rmdopen-2021-001679","volume":"7","author":"K Sweet","year":"2021","unstructured":"Sweet K, Song Q, Loza MJ et al (2021) Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials. RMD Open 7:e001679. https:\/\/doi.org\/10.1136\/rmdopen-2021-001679","journal-title":"RMD Open"},{"key":"6745_CR23","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40744-022-00444-x","volume":"9","author":"G Schett","year":"2022","unstructured":"Schett G, Loza MJ, Palanichamy A et al (2022) Collagen turnover biomarkers associate with active psoriatic arthritis and decrease with guselkumab treatment in a phase 3 clinical trial (DISCOVER-2). Rheumatol Ther 9:1017\u20131030. https:\/\/doi.org\/10.1007\/s40744-022-00444-x","journal-title":"Rheumatol Ther"},{"key":"6745_CR24","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1136\/ard.2006.056457","volume":"66","author":"SJ Bond","year":"2007","unstructured":"Bond SJ, Farewell VT, Schentag CT et al (2007) Predictors for radiological damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis 66:370\u2013376. https:\/\/doi.org\/10.1136\/ard.2006.056457","journal-title":"Ann Rheum Dis"},{"key":"6745_CR25","first-page":"45","volume":"30","author":"P Simon","year":"2012","unstructured":"Simon P, Pfoehler C, Bergner R et al (2012) Swollen joint count in psoriatic arthritis is associated with progressive radiological damage in hands and feet. Clin Exp Rheumatol 30:45\u201350","journal-title":"Clin Exp Rheumatol"},{"key":"6745_CR26","doi-asserted-by":"publisher","unstructured":"van der Heijde D, Sharp J, Wassenberg S et al (2005) Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis 64 Suppl 2:ii61-ii64. https:\/\/doi.org\/10.1136\/ard.2004.030809","DOI":"10.1136\/ard.2004.030809"},{"key":"6745_CR27","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","volume":"75","author":"MM Schoels","year":"2016","unstructured":"Schoels MM, Aletaha D, Alasti F et al (2016) Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 75:811\u2013818. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207507","journal-title":"Ann Rheum Dis"},{"key":"6745_CR28","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/ard.2009.122259","volume":"69","author":"M Schoels","year":"2010","unstructured":"Schoels M, Aletaha D, Funovits J et al (2010) Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 69:1441\u20131447. https:\/\/doi.org\/10.1136\/ard.2009.122259","journal-title":"Ann Rheum Dis"},{"key":"6745_CR29","doi-asserted-by":"publisher","unstructured":"Tillett W, Day J, McHugh NJ et al (2021) Oral presentation 0224. Continuous composite measures for routine care in psoriatic arthritis: thresholds of meaning and clinically important difference estimates for the 3 and 4 VAS scales from a UK multicentre study. Ann Rheum Dis 80:135. https:\/\/doi.org\/10.1136\/annrheumdis-2021-eular.1622","DOI":"10.1136\/annrheumdis-2021-eular.1622"},{"key":"6745_CR30","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.3899\/jrheum.150165","volume":"42","author":"M Geijer","year":"2015","unstructured":"Geijer M, Lindqvist U, Husmark T et al (2015) The Swedish early psoriatic arthritis registry 5-year followup: substantial radiographic progression mainly in men with high disease activity and development of dactylitis. J Rheumatol 42:2110\u20132117. https:\/\/doi.org\/10.3899\/jrheum.150165","journal-title":"J Rheumatol"},{"key":"6745_CR31","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/annrheumdis-2016-209511","volume":"76","author":"D Aletaha","year":"2017","unstructured":"Aletaha D, Alasti F, Smolen JS (2017) Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression. Ann Rheum Dis 76:418\u2013421. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209511","journal-title":"Ann Rheum Dis"},{"key":"6745_CR32","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1136\/annrheumdis-2023-eular.604","volume":"82","author":"S Siebert","year":"2023","unstructured":"Siebert S, Schett G, Raychaudhuri SP et al (2023) AB1085 Changes in serum cytokines and collagen proteins correlate with durability of guselkumab efficacy and continued disease improvement through 2 years in patients with active psoriatic arthritis. Ann Rheum Dis 82:1763\u20131764. https:\/\/doi.org\/10.1136\/annrheumdis-2023-eular.604","journal-title":"Ann Rheum Dis"},{"key":"6745_CR33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40744-021-00420-x","volume":"9","author":"A Ogdie","year":"2022","unstructured":"Ogdie A, Tillett W, Booth N et al (2022) Usage of C-reactive protein testing in the diagnosis and monitoring of psoriatic arthritis (PsA): results from a real-world survey in the USA and Europe. Rheumatol Ther 9:285\u2013293. https:\/\/doi.org\/10.1007\/s40744-021-00420-x","journal-title":"Rheumatol Ther"},{"key":"6745_CR34","doi-asserted-by":"publisher","unstructured":"Gialouri CG, Evangelatos G, Pappa M et al (2022) Normal C-reactive protein in active psoriatic arthritis: results from real-world clinical practice. Ther Adv Musculoskelet Dis 14:\u00a0https:\/\/doi.org\/10.1177\/1759720X221122417","DOI":"10.1177\/1759720X221122417"},{"key":"6745_CR35","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1136\/annrheumdis-2019-215960","volume":"79","author":"RSG Goncalves","year":"2020","unstructured":"Goncalves RSG, de Almeida Martins LM, de Ataide Mariz H et al (2020) DAPSA versus cDAPSA: do we need to use CRP? Ann Rheum Dis 79:e142. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215960","journal-title":"Ann Rheum Dis"},{"key":"6745_CR36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1136\/annrheumdis-2017-211998","volume":"77","author":"LJJ van Mens","year":"2018","unstructured":"van Mens LJJ, van de Sande MGH, van Kuijk AWR et al (2018) Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort. Ann Rheum Dis 77:251\u2013257. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211998","journal-title":"Ann Rheum Dis"},{"key":"6745_CR37","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/rheumatology\/keac500","volume":"62","author":"PJ Mease","year":"2023","unstructured":"Mease PJ, McInnes IB, Tam LS et al (2023) Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis. Rheumatology (Oxford) 62:1417\u20131425. https:\/\/doi.org\/10.1093\/rheumatology\/keac500","journal-title":"Rheumatology (Oxford)"},{"key":"6745_CR38","unstructured":"Chandran V, Thavaneswaran A, Cook RJ et al\u00a0 (2014) Abstract 1592. Ability of clinical variables to predict radiographic damage in psoriatic arthritis. ACR\/ARHP Annual Meeting"},{"key":"6745_CR39","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/annrheumdis-2012-201357","volume":"72","author":"L Eder","year":"2013","unstructured":"Eder L, Thavaneswaran A, Chandran V et al (2013) Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis. Ann Rheum Dis 72:578\u2013582. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201357","journal-title":"Ann Rheum Dis"},{"key":"6745_CR40","doi-asserted-by":"publisher","first-page":"849560","DOI":"10.3389\/fimmu.2022.849560","volume":"13","author":"NL Bragazzi","year":"2022","unstructured":"Bragazzi NL, Bridgewood C, Watad A et al (2022) Sex-based medicine meets psoriatic arthritis: lessons learned and to learn. Front Immunol 13:849560. https:\/\/doi.org\/10.3389\/fimmu.2022.849560","journal-title":"Front Immunol"},{"key":"6745_CR41","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3899\/jrheum.220928","volume":"50","author":"P Rahman","year":"2023","unstructured":"Rahman P, Boehncke WH, Mease PJ et al (2023) Safety of guselkumab with and without prior tumor necrosis factor inhibitor treatment: pooled results across 4 studies in patients with psoriatic arthritis. J Rheumatol 50:769-780.\u00a0https:\/\/doi.org\/10.3899\/jrheum.220928","journal-title":"J Rheumatol"},{"key":"6745_CR42","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.3899\/jrheum.201532","volume":"48","author":"P Rahman","year":"2021","unstructured":"Rahman P, Ritchlin CT, Helliwell PS et al (2021) Pooled safety results through 1 year of 2 phase III trials of guselkumab in patients with psoriatic arthritis. J Rheumatol 48:1815\u20131823. https:\/\/doi.org\/10.3899\/jrheum.201532","journal-title":"J Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06745-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06745-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06745-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T15:08:20Z","timestamp":1704726500000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06745-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,3]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["6745"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06745-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,3]]},"assertion":[{"value":"29 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The DISCOVER-2 trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The protocol was approved by each site\u2019s governing ethical body, and all patients provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"<b>PJM<\/b> has received research support, consulting fees, and\/or speaker bureau support from AbbVie, Acelyrin, Aclaris, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Inmagene, Janssen, MoonLake Immunotherapeutics, Novartis, Pfizer, Sun Pharma, UCB, Ventyx, and Xinthera. <b>ABG<\/b> has received honoraria as an advisory board member and consultant for Amgen, AnaptypsBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dice Therapeutics, Eli Lilly, Janssen, Novartis, Sanofi, UCB, and Xbiotech, and has received research\/educational grants from AnaptypsBio, Bristol Myers Squibb, Moonlake Immunotherapeutics AG, Novartis, and UCB (all paid to Mount Sinai School of Medicine). <b>AO<\/b> has received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, CorEvitas, Eli Lilly, Gilead, Happify Health, Janssen, Novartis, Pfizer, and UCB; grant\/research support to the University of Pennsylvania from AbbVie, Janssen, Novartis, and Pfizer, and to Forward from Amgen. Her husband has received royalties from Novartis. <b>IBM<\/b> has received consulting fees from AbbVie, Amgen, Astra Zeneca, Bristol Myers Squibb, Cabaletta, Compugen, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, Roche, Sanofi, and UCB; grant\/research support from Amgen, Astra Zeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Roche, and UCB; and is a shareholder of Causeway Therapeutics, and Evelo Compugen, <b>SDC<\/b> is an employee of Janssen Scientific Affairs, LLC and owns stock or stock options in Johnson & Johnson, of which Janssen Scientific Affairs, LLC is a wholly owned subsidiary. <b>ER<\/b> is a consultant of Janssen and an employee of JSS Medical Research. <b>AK<\/b> is an employee of Janssen Research & Development, LLC, a wholly owned subsidiary of Johnson & Johnson, and owns stocks in Johnson & Johnson. <b>XLX<\/b> is an employee of Janssen Research & Development. <b>MS<\/b> is an employee of Janssen Research & Development and owns stock or stock options in Johnson & Johnson. <b>FL<\/b> is an employee of Immunology Global Medical Affairs, Janssen Pharmaceutical Companies and owns stock in Johnson & Johnson. <b>MK<\/b> has received consulting fees and\/or speakers fees from\u00a0AbbVie, Amgen, Asahi-Kasei Pharma, Astellas, Ayumi Pharma, Bristol Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Tanabe-Mitsubishi, and UCB. <b>PR<\/b> has received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB; travel support from Janssen; and grants from Janssen, and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}